BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
BiondVax’s go-to-market strategy for its lead candidate M-001, universal flu vaccine is to initially obtain regulatory approval as a primer to a pandemic or seasonal vaccine, and following the accumulation of enough data, to test and gain approval as a universal standalone vaccine.
Learn more about the Flu
We have put together a short movie to help you understand more about the flu virus and how today’s vaccine don’t go far enough in protecting us. Please watch our movie.